Trial Profile
Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in patients diagnosed with refractory diffuse large B-cell lymphoma not candidates for high-dose chemotherapy and hematopoietic progenitor cell transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Jun 2022 Results published in the Clinical Cancer Research
- 30 Oct 2014 New trial record